JNJ-54179060

DRUG3 trials

Sponsors

Janssen - Cilag International, Janssen Research & Development, LLC

Conditions

Leukemia, Lymphocytic, Chronic, B-CellLeukemia, Myeloid, AcuteLymphoma, Non-HodgkinMetastatic Castration-resistant Prostate Cancer (mCRPC)Myelodysplastic SyndromesNeoplasmsRelapsed/Refractory Mantle Cell LymphomaSolid Tumor, Adult

Phase 1

A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring

Enrolling by invitationNCT06788509

Janssen Research & Development, LLCLeukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute, Lymphoma, Non-Hodgkin +4

Start: 2024-12-30End: 2028-01-21Target: 80Updated: 2025-10-10

Phase 2

A Randomized, Controlled, Open-label, Multicenter, Inferentially Seamless Phase 2/3 Study of Ibrutinib in Combination With Rituximab Versus Physician’s Choice of Lenalidomide Plus Rituximab or Bortezomib Plus Rituximab in Participants with Relapsed or Refractory Mantle Cell Lymphoma

CompletedCTIS2023-503618-64-00

Janssen - Cilag InternationalRelapsed/Refractory Mantle Cell Lymphoma

Start: 2022-11-16End: 2024-09-18Target: 7Updated: 2024-04-24

Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia

RecruitingCTIS2023-504044-34-00

Janssen - Cilag InternationalUntreated Chronic Lymphocytic Leukemia

Start: 2024-04-17Target: 213Updated: 2026-01-19